S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:ACOR

Acorda Therapeutics Stock Forecast, Price & News

$0.92
+0.03 (+3.39 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.84
Now: $0.92▼
$0.96
50-Day Range
$0.45
MA: $0.63▼
$0.96
52-Week Range
$0.42
Now: $0.92▼
$2.78
Volume2.11 million shs
Average Volume3.30 million shs
Market Capitalization$43.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.42
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Read More
Acorda Therapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.49 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ACOR
Previous Symbol
CUSIP00484M10
CIK1008848
Webwww.acorda.com
Phone914-347-4300
Employees344

Debt

Debt-to-Equity Ratio0.54
Current Ratio1.14
Quick Ratio0.90

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$192.41 million
Price / Sales0.23
Cash Flow$5.38 per share
Price / Cash Flow0.17
Book Value$6.47 per share
Price / Book0.14

Profitability

EPS (Most Recent Fiscal Year)($1.99)
Net Income$-272,970,000.00
Net Margins-138.66%
Return on Equity-19.55%
Return on Assets-7.36%

Miscellaneous

Outstanding Shares47,968,000
Market Cap$43.89 million
Next Earnings Date11/3/2020 (Confirmed)
OptionableOptionable
$0.92
+0.03 (+3.39 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

How has Acorda Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Acorda Therapeutics' stock was trading at $1.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ACOR shares have decreased by 9.4% and is now trading at $0.9150.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Acorda Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acorda Therapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Acorda Therapeutics.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Acorda Therapeutics.

How can I listen to Acorda Therapeutics' earnings call?

Acorda Therapeutics will be holding an earnings conference call on Tuesday, November 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics, Inc. (NASDAQ:ACOR) posted its quarterly earnings data on Tuesday, August, 4th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.64) by $0.27. The biopharmaceutical company earned $33.62 million during the quarter, compared to analyst estimates of $26.35 million. Acorda Therapeutics had a negative net margin of 138.66% and a negative return on equity of 19.55%.
View Acorda Therapeutics' earnings history.

What price target have analysts set for ACOR?

4 brokers have issued twelve-month target prices for Acorda Therapeutics' shares. Their forecasts range from $1.00 to $10.00. On average, they anticipate Acorda Therapeutics' stock price to reach $5.33 in the next twelve months. This suggests a possible upside of 482.9% from the stock's current price.
View analysts' price targets for Acorda Therapeutics.

Are investors shorting Acorda Therapeutics?

Acorda Therapeutics saw a decline in short interest in the month of October. As of October 15th, there was short interest totaling 9,660,000 shares, a decline of 23.3% from the September 30th total of 12,600,000 shares. Based on an average trading volume of 5,700,000 shares, the days-to-cover ratio is presently 1.7 days. Approximately 20.5% of the company's shares are short sold.
View Acorda Therapeutics' Short Interest.

Who are some of Acorda Therapeutics' key competitors?

Some companies that are related to Acorda Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN) and Ionis Pharmaceuticals (IONS).
View all competitors.

What other stocks do shareholders of Acorda Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acorda Therapeutics investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), ADMA Biologics (ADMA), InterDigital (IDCC), Nektar Therapeutics (NKTR), Rigel Pharmaceuticals (RIGL), Novan (NOVN), SCYNEXIS (SCYX), Acasti Pharma (ACST) and Applied Materials (AMAT).

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the following people:
  • Dr. Ron Cohen, Founder, CEO, Pres & Director (Age 64, Pay $827.95k)
  • Mr. David Lawrence, CTO, Chief of Bus. Operations & Principal Accounting Officer (Age 62, Pay $480.9k)
  • Ms. Jane Wasman, Consultant (Age 64, Pay $1.85M)
  • Ms. Lauren M. Sabella, Chief Commercial Officer (Age 59, Pay $490.07k)
  • Dr. Burkhard Blank, Chief Medical Officer and Head of R&D (Age 65, Pay $662.5k)

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $0.92.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $43.89 million and generates $192.41 million in revenue each year. The biopharmaceutical company earns $-272,970,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Acorda Therapeutics employs 344 workers across the globe.

What is Acorda Therapeutics' official website?

The official website for Acorda Therapeutics is www.acorda.com.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.

This page was last updated on 10/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.